国际呼吸杂志
國際呼吸雜誌
국제호흡잡지
INTERNATIONAL JOURNAL OF RESPIRATION
2013年
16期
1236-1239
,共4页
培美曲塞%非小细胞肺癌%老年
培美麯塞%非小細胞肺癌%老年
배미곡새%비소세포폐암%노년
Pemetrexed%Non-small cell lung cancer%Elderly
目的 探讨培美曲塞单药一线治疗老年晚期非鳞非小细胞肺癌的临床疗效及不良反应.方法 经病理或细胞学确诊老年(70～85岁)晚期(ⅢB～Ⅳ期)肺腺癌患者86例,46例患者接受培美曲塞500mg/m2治疗；40例患者接受多西他赛75 mg/m2治疗,每组至少接受2个周期以上化疗,每2个周期评估疗效、不良反应.结果 培美曲塞组和多西他赛组有效率分别是26.1％和22.5％(P=0.699);疾病控制率分别是65.2％和60.0％(P=0.618);中位无进展生存期分别是4.0个月和3.5个月(P=0.500).两组主要的不良反应是骨髓抑制和胃肠道反应,但差异无统计学意义；培美曲塞组脱发和乏力的发生率低于多西他赛组(P＜0.05).结论 培美曲塞单药治疗老年非鳞非小细胞肺癌疗效均较好,且培美曲塞不良反应低于多西他赛,可以推荐作为一线药物使用.
目的 探討培美麯塞單藥一線治療老年晚期非鱗非小細胞肺癌的臨床療效及不良反應.方法 經病理或細胞學確診老年(70～85歲)晚期(ⅢB～Ⅳ期)肺腺癌患者86例,46例患者接受培美麯塞500mg/m2治療；40例患者接受多西他賽75 mg/m2治療,每組至少接受2箇週期以上化療,每2箇週期評估療效、不良反應.結果 培美麯塞組和多西他賽組有效率分彆是26.1％和22.5％(P=0.699);疾病控製率分彆是65.2％和60.0％(P=0.618);中位無進展生存期分彆是4.0箇月和3.5箇月(P=0.500).兩組主要的不良反應是骨髓抑製和胃腸道反應,但差異無統計學意義；培美麯塞組脫髮和乏力的髮生率低于多西他賽組(P＜0.05).結論 培美麯塞單藥治療老年非鱗非小細胞肺癌療效均較好,且培美麯塞不良反應低于多西他賽,可以推薦作為一線藥物使用.
목적 탐토배미곡새단약일선치료노년만기비린비소세포폐암적림상료효급불량반응.방법 경병리혹세포학학진노년(70～85세)만기(ⅢB～Ⅳ기)폐선암환자86례,46례환자접수배미곡새500mg/m2치료；40례환자접수다서타새75 mg/m2치료,매조지소접수2개주기이상화료,매2개주기평고료효、불량반응.결과 배미곡새조화다서타새조유효솔분별시26.1％화22.5％(P=0.699);질병공제솔분별시65.2％화60.0％(P=0.618);중위무진전생존기분별시4.0개월화3.5개월(P=0.500).량조주요적불량반응시골수억제화위장도반응,단차이무통계학의의；배미곡새조탈발화핍력적발생솔저우다서타새조(P＜0.05).결론 배미곡새단약치료노년비린비소세포폐암료효균교호,차배미곡새불량반응저우다서타새,가이추천작위일선약물사용.
Objective To investigate the clinical effect and side-effect of pemetrexed alone as firstline drug in the treatment for elderly patients with non squamous cell carcinoma of non-small cell lung cancer (NSCLC).Methods Eighty-six elderly patients with non squamous cell carcinoma of NSCLC stage Ⅲ B～ Ⅳ confirmed by pathology or cytology were divided into permetrexed group (n =46) and docetaxel group (n =40).Patients in pemetrexed group received pemetrexed 500 mg/m2,while patients in docetaxel group received docetaxel 75 mg/m2.All patients received at least two cycles chemotherapy and the clinical effect and side-effect were evaluated every two cycles.Results The response rate in pemetrexed group and docetaxel group was 26.1％ and 22.5 ％ (P =0.699) respectively,and the clinical benefit rate was 65.2％ and 60.0％ (P =0.618) respectively.The median progression free survival time was 4.0 and 3.5 months (P =0.500) respectively.The main side effects were myelosuppression and gastrointestinal toxicity.The incidence of fatigue alopecie in pemetrexed group were significantly less than that in docetaxel group (P ＜0.05).Conclusions Chemotherapy with pemetrexed for elderly patients with non squamous cell carcinoma of NSCLC is effective and the side-effect of pemetrexed is lower than that of docetaxel.
